Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.35 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30952819 | 1.00 | LMNA (0.38) | LMNAALDH1A1EHMT2EHMT1APOBEC3G | |
| Hydrochloric Acid SCHEMBL30767142 | 0.99 | LMNA (0.37) | LMNAALDH1A1EHMT2EHMT1APOBEC3G | |
| SCHEMBL22414810 | 0.90 | LMNA (0.38) | LMNAALDH1A1EHMT2EHMT1APOBEC3G | |
| SCHEMBL29414992 | 0.90 | LMNA (0.38) | LMNAALDH1A1EHMT2EHMT1APOBEC3G | |
| SCHEMBL17059143 | 0.89 | LMNA (0.32) | LMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL30767154 | 0.89 | LMNA (0.38) | LMNAALDH1A1EHMT2EHMT1APOBEC3G | |
| SCHEMBL20703297 | 0.89 | LMNA (0.39) | LMNAALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL27094915 | 0.87 | HPGD (0.34) | LMNAALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL27094913 | 0.85 | SMN1; SMN2 (0.34) | LMNAALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL17930872 | 0.83 | LMNA (0.34) | LMNAALDH1A1EHMT2EHMT1APOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676543-A1 | METHODS OF TREATING CANCER USING ANTI-HER2 ANTIBODY-DRUG CONJUGATES AND HER2 KINASE INHIBITORS | Seagen Inc. (US) | 2026-01-14 | — | — | EP | claimed |
| WO-2025038638-A1 | METHODS OF TREATING CANCER USING ANTI-HER2 ANTIBODY-DRUG CONJUGATES | SEAGEN INC. (US) | 2025-02-20 | — | — | WO | claimed |
| WO-2024191826-A1 | METHODS OF TREATING CANCER USING ANTI-HER2 ANTIBODY-DRUG CONJUGATES AND HER2 KINASE INHIBITORS | SEAGEN INC. (US) | 2024-09-19 | — | — | WO | claimed |
| EP-3845252-A1 | USE OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE IN TREATING UROTHELIAL CARCINOMA | RemeGen, Ltd. (CN) | 2021-07-07 | — | — | EP | claimed |
| US-20200289663-A1 | USE OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE IN TREATING UROTHELIAL CARCINOMA | REMEGEN, LTD (CN) | 2020-09-17 | — | — | US | claimed |
| US-20260034236-A1 | NEW DRUG COMPLEX | KOWA COMPANY, LTD. (JP) | 2026-02-05 | — | — | US | disclosed |
| EP-4676543-A1 | METHODS OF TREATING CANCER USING ANTI-HER2 ANTIBODY-DRUG CONJUGATES AND HER2 KINASE INHIBITORS | Seagen Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-4570272-A1 | NEW DRUG COMPLEX | KOWA COMPANY, LTD. (JP) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025038638-A1 | METHODS OF TREATING CANCER USING ANTI-HER2 ANTIBODY-DRUG CONJUGATES | SEAGEN INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| EP-3452096-B1 | BICYCLIC PEPTIDE-TOXIN CONJUGATES SPECIFIC FOR MT1-MMP | BICYCLERD LTD (GB) | 2025-01-29 | — | — | EP | disclosed |
| WO-2024191826-A1 | METHODS OF TREATING CANCER USING ANTI-HER2 ANTIBODY-DRUG CONJUGATES AND HER2 KINASE INHIBITORS | SEAGEN INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| CN-113039191-B | Nucleotide analogues | 奇异基因组学系统公司 | 2024-07-16 | — | — | CN | disclosed |
| WO-2015028850-A1 | NOVEL CYTOTOXIC AGENTS FOR CONJUGATION OF DRUGS TO CELL BINDING MOLECULE | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2015-03-05 | — | — | WO | disclosed |
| US-20140045919-A1 | Folate Conjugates | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045919-A1 | Folate Conjugates | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8507455-B2 | Folate conjugates | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507455-B2 | Folate conjugates | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20090247614-A1 | Folate Conjugates | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247614-A1 | Folate Conjugates | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009082606-A2 | FOLATE CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034236-A1 | NEW DRUG COMPLEX | OPRM1, ABCC1, OPRD1 | LMNA 2523/4885ALDH1A1 2282/4885EHMT2 4630/4885 |
| US-20090247614-A1 | Folate Conjugates | FOLR2, FOLR1, NSUN2 | LMNA 1122/4885ALDH1A1 3642/4885EHMT2 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.